Healthcare reports little hiring during October
The healthcare industry saw little job creation in October, adding about 11,600 positions, while the overall U.S. unemployment rate was pegged at 9%. Healthcare jobs held steady at 14.2 million with an increase of less than 0.1%, based on preliminary figures from the U.S. Bureau of Labor Statistics. Last month, the bureau reported the overall U.S. unemployment rate at 9.1%. Healthcare added an average of 27,957 jobs a month during the 12-month period ended in October, according to seasonally adjusted figures. During that period, the industry added 367,500 jobs, for a 2.7% hike since October 2010. Job growth at hospitals slowed to less than 1%, adding 3,300 jobs for the month to a workforce of 4.8 million. Outpatient-care centers saw the largest percentage increase, rising nearly 0.5% for 2,900 new jobs. Outpatient care employs about 630,000 people overall. Physician offices, which saw a large bump in September, continued to grow, albeit at a rate similar to other healthcare fields. Doctors’ offices added 2,200 jobs at about a 1% clip in October to a workforce of 2.4 million. was formed last year after Mckesson acquired US Oncology. Broussard had served as chairman and CEO of US Oncology before the $2.16 billion deal was announced in November. His appointment at Humana is effective in December. Mccallister, Humana’s chairman and CEO, will retire in the next 12 to 18 months, according to a news release. He is 59. The Louisville, Ky.based insurer also said it promoted Chief Operating Officer James Murray, 57, to executive vice president. Mccallister, Broussard and Murray will join the office of the chairman, an initiative that “Mccallister is creating to guide the company in key strategic areas and ensure a smooth leadership transition,” according to the Humana release. A spokeswoman at Mckesson Specialty Health said the company is conducting an internal and external search to identify a successor for Broussard. standing matters which do not reflect the company that we are today,” Glaxosmithkline CEO Andrew Witty said in the statement. “In recent years, we have fundamentally changed our procedures for compliance, marketing and selling in the U.S. to ensure that we operate with high standards of integrity and that we conduct our business openly and transparently.” The company said it developed a new incentive compensation system that awards sales representatives on the quality of services they provide to healthcare professionals rather than individual sales targets as the basis for bonuses. The sum would exceed the $2.3 billion that Pfizer agreed to pay in 2009, which the Justice Department had said was the largest-ever healthcare fraud settlement.